Cabergoline in Nonfunctioning Pituitary Adenomas
A phase 3 trial of Cabergoline in Pituitary tumours, run by University of Sao Paulo General Hospital, completed.
Overview
Cabergoline in Nonfunctioning Pituitary Adenomas is a phase 3 interventional study registered as NCT03271918 by University of Sao Paulo General Hospital, with 140 participants recorded, started 2015-02-01 and reaching its primary completion in 2017-02-01. Interventions recorded: Cabergoline. Conditions recorded: Pituitary Adenoma, Nonfunctioning Pituitary Adenoma.
Linked to the drug Cabergoline because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Shares Cabergoline, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialSafety and Potency of a High Cabergoline Dosage in Microprolactinomas
Shares Cabergoline, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialMulticenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialSafety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialEfficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialStrict IGF-1 Control in Acromegaly
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialA Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialSafety and Efficacy of LCI699 in Cushing's Disease Patients
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.